Snowden Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.57M | Buy |
7,247
+1,236
| +21% | +$671K | 0.09% | 219 |
|
|
2025
Q4 | $3.49M | Buy |
6,011
+170
| +3% | +$96.1K | 0.09% | 222 |
|
|
2025
Q3 | $2.84M | Sell |
5,841
-1,233
| -17% | -$574K | 0.08% | 252 |
|
|
2025
Q2 | $2.87M | Sell |
7,074
-381
| -5% | -$159K | 0.08% | 239 |
|
|
2025
Q1 | $3.71M | Sell |
7,455
-197
| -3% | -$107K | 0.12% | 187 |
|
|
2024
Q4 | $3.98M | Sell |
7,652
-874
| -10% | -$481K | 0.12% | 176 |
|
|
2024
Q3 | $5.28M | Sell |
8,526
-245
| -3% | -$145K | 0.16% | 154 |
|
|
2024
Q2 | $4.85M | Sell |
8,771
-164
| -2% | -$94K | 0.14% | 179 |
|
|
2024
Q1 | $5.2M | Buy |
8,935
+3,522
| +65% | +$1.98M | 0.16% | 167 |
|
|
2023
Q4 | $2.87M | Sell |
5,413
-428
| -7% | -$207K | 0.11% | 231 |
|
|
2023
Q3 | $2.96M | Sell |
5,841
-7,379
| -56% | -$3.93M | 0.13% | 216 |
|
|
2023
Q2 | $6.9M | Sell |
13,220
-462
| -3% | -$249K | 0.25% | 96 |
|
|
2023
Q1 | $7.89M | Buy |
13,682
+174
| +1% | +$98.1K | 0.31% | 69 |
|
|
2022
Q4 | $7.44M | Buy |
13,508
+1,408
| +12% | +$746K | 0.31% | 68 |
|
|
2022
Q3 | $6.14M | Sell |
12,100
-245
| -2% | -$137K | 0.28% | 80 |
|
|
2022
Q2 | $6.71M | Buy |
12,345
+305
| +3% | +$168K | 0.3% | 75 |
|
|
2022
Q1 | $7.11M | Buy |
12,040
+2,636
| +28% | +$1.51M | 0.28% | 81 |
|
|
2021
Q4 | $6.28M | Sell |
9,404
-2,547
| -21% | -$1.59M | 0.32% | 80 |
|
|
2021
Q3 | $6.83M | Buy |
11,951
+141
| +1% | +$77.4K | 0.34% | 68 |
|
|
2021
Q2 | $5.96M | Buy |
11,810
+662
| +6% | +$312K | 0.3% | 81 |
|
|
2021
Q1 | $5.09M | Sell |
11,148
-9,266
| -45% | -$4.42M | 0.29% | 91 |
|
|
2020
Q4 | $9.51M | Buy |
20,414
+1,475
| +8% | +$692K | 0.63% | 20 |
|
|
2020
Q3 | $8.36M | Buy |
18,939
+6,624
| +54% | +$2.74M | 0.67% | 21 |
|
|
2020
Q2 | $4.46M | Buy |
12,315
+3,438
| +39% | +$1.15M | 0.38% | 72 |
|
|
2020
Q1 | $2.52M | Buy |
8,877
+181
| +2% | +$57.1K | 0.27% | 114 |
|
|
2019
Q4 | $2.83M | Buy |
8,696
+148
| +2% | +$44.9K | 0.25% | 128 |
|
|
2019
Q3 | $2.49M | Sell |
8,548
-157
| -2% | -$45K | 0.25% | 139 |
|
|
2019
Q2 | $2.56M | Sell |
8,705
-139
| -2% | -$38.3K | 0.26% | 137 |
|
|
2019
Q1 | $2.42M | Buy |
8,844
+43
| +0.5% | +$10.7K | 0.26% | 135 |
|
|
2018
Q4 | $1.97M | Buy |
8,801
+135
| +2% | +$31.7K | 0.26% | 139 |
|
|
2018
Q3 | $2.12M | Buy |
8,666
+205
| +2% | +$47.2K | 0.24% | 137 |
|
|
2018
Q2 | $1.75M | Buy |
8,461
+81
| +1% | +$17.2K | 0.23% | 156 |
|
|
2018
Q1 | $1.73M | Buy |
8,380
+6,994
| +505% | +$1.47M | 0.25% | 144 |
|
|
2017
Q4 | $263K | Buy |
1,386
+77
| +6% | +$14.8K | 0.04% | 348 |
|
|
2017
Q3 | $248K | Buy |
+1,309
| New | +$237K | 0.04% | 337 |
|
|
2017
Q2 | – | Sell |
-1,360
| Closed | -$209K | – | 364 |
|
|
2017
Q1 | $209K | Buy |
+1,360
| New | +$208K | 0.05% | 316 |
|
Other funds holding TMO
VCM
Snowden Capital Advisors's TMO Position: Q1 2026 in Review
Snowden Capital Advisors increased its Thermo Fisher Scientific (TMO) stake by 21% in Q1 2026, buying an estimated $671K and bringing the position to 7,247 shares worth $3.57M. The position accounts for 0.09% of the portfolio, ranked #219.
Snowden Capital Advisors first reported a position in TMO in Q1 2017 and has held it in 36 quarters since. The position peaked at $9.51M in Q4 2020. 2,589 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Snowden Capital Advisors held 7,247 shares of Thermo Fisher Scientific worth $3.57M as of Q1 2026.
- Snowden Capital Advisors bought 1,236 Thermo Fisher Scientific shares in Q1 2026, an estimated $671K.
- Thermo Fisher Scientific made up 0.09% of Snowden Capital Advisors's portfolio in Q1 2026, its #219 holding.
- Snowden Capital Advisors first reported a position in Thermo Fisher Scientific in Q1 2017 and has held it in 36 quarters since.
- Snowden Capital Advisors's Thermo Fisher Scientific position peaked at $9.51M in Q4 2020.
- 2,589 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.